KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Intangibles (2017 - 2024)

Aquestive Therapeutics has reported Intangibles over the past 8 years, most recently at $1.2 million for Q1 2024.

  • For Q1 2024, Intangibles fell 11.25% year-over-year to $1.2 million; the TTM value through Mar 2024 reached $1.2 million, down 11.25%, while the annual FY2023 figure was $1.3 million, 10.94% down from the prior year.
  • Intangibles for Q1 2024 was $1.2 million at Aquestive Therapeutics, down from $1.3 million in the prior quarter.
  • Over five years, Intangibles peaked at $7.4 million in Q2 2020 and troughed at $25000.0 in Q2 2022.
  • A 5-year average of $1.5 million and a median of $1.2 million in 2024 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: plummeted 99.14% in 2021 and later skyrocketed 5328.0% in 2023.
  • Year by year, Intangibles stood at $102000.0 in 2020, then plummeted by 50.0% to $51000.0 in 2021, then skyrocketed by 2713.73% to $1.4 million in 2022, then decreased by 10.94% to $1.3 million in 2023, then decreased by 3.05% to $1.2 million in 2024.
  • Business Quant data shows Intangibles for AQST at $1.2 million in Q1 2024, $1.3 million in Q4 2023, and $1.3 million in Q3 2023.